Double Filtration Plasmapheresis (DFPP) and Lipid Metabolism
NCT ID: NCT03491956
Last Updated: 2021-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2018-02-01
2021-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
NCT02923193
SFA TReatment and vAscular Functions
NCT03811925
Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia
NCT07340112
Endovascular Treatment of Peripheral Artery Disease (PAD)
NCT03414515
Comparison of a Lithotripsy vs Standard Preparation Followed by Stenting With Supera Stent in Femoropopliteal Lesions
NCT06112171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DFPP group
self contrast (before and after DFPP)
DFPP
Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DFPP
Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Severe cardiopulmonary insufficiency
3. tumor
4. pregnancy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Pudong Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jin HM, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Yu, doctor
Role: PRINCIPAL_INVESTIGATOR
Shanghai Pudong Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Pudong Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huimin Jin, doctor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Zhang XM, Gu YH, Deng H, Xu ZQ, Zhong ZY, Lyu XJ, Jin HM, Yang XH. Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs. Front Cardiovasc Med. 2021 Jul 7;8:691336. doi: 10.3389/fcvm.2021.691336. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiPudongH2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.